BC Extra | Jan 11, 2020
Company News

Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV

Led by a team of veterans from Alios BioPharma and Janssen, Aligos Therapeutics raised $125 million in a series B round to bring three of its HBV therapies to the clinic this year. Aligos thinks...
BC Extra | Oct 7, 2019
Clinical News

Latest aldafermin data in NASH weigh on NGM shares

NGM shed $2.77 (20%) to $10.78 on Monday as investors appeared underwhelmed by Phase II data for aldafermin in NASH. Interim 24-week data from cohort 4 of an adaptive Phase II trial showed that treatment...
BC Extra | Apr 11, 2019
Clinical News

Gilead’s NASH combo data suggest benefit, safety

Phase II combination data presented by Gilead at EASL could begin to lay the groundwork for what MOAs will be essential parts of combinations in non-alcoholic steatohepatitis. In a Phase II proof-of-concept trial in 20...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BC Week In Review | Oct 5, 2018
Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

Abstracts with Phase II data for several non-alcoholic steatohepatitis therapies were published ahead of next month's American Association for the Study of Liver Diseases meeting in San Francisco. Among them, Gilead Sciences Inc. (NASDAQ:GILD) reported...
BC Innovations | Oct 4, 2018
Distillery Therapeutics

Inflammation

INDICATION: Shock/trauma Mouse studies suggest levothyroxine could help treat traumatic brain injury (TBI). In a mouse model of TBI, levothyroxine decreased cognitive deficits compared with vehicle. Next steps could include testing levothyroxine in additional models...
BC Extra | Oct 2, 2018
Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

Abstracts with Phase II data for several non-alcoholic steatohepatitis therapies were published ahead of next month's American Association for the Study of Liver Diseases meeting in San Francisco. Among them, Gilead Sciences Inc. (NASDAQ:GILD) reported...
BC Week In Review | Sep 28, 2018
Financial News

CRISPR, Viking, Fate, Molecular Templates price follow-ons

CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each priced follow-ons late on Sept. 20, raising a total of $545.9 million. CRISPR raised $200 million through...
BC Week In Review | Sep 21, 2018
Clinical News

Viking's VK2809 meets in Phase II for NAFLD

Viking Therapeutics Inc. (NASDAQ:VKTX) reported that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD). The company plans to meet with FDA early next year...
BC Extra | Sep 21, 2018
Financial News

Follow-on roundup: CRISPR, Viking, Fate, Molecular Templates

CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each priced follow-ons late Thursday, raising a total of $545.9 million. CRISPR raised $200 million through the sale...
Items per page:
1 - 10 of 153